Houston’s huge R&D hub takes center stage in feds’ campaign to clip China’s ties to researchers, IP theft

Amber Tong

Houston’s prized biomedical research hub has found itself in the eye of a diplomatic storm that erupted after the US abruptly ordered China to close …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Houston’s huge R&D hub takes center stage in feds’ campaign to clip China’s ties to researchers, IP theft

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Trump 2.0 blog: Wayback Machine is insufficient for US health data, judge says

Travere plans to seek expanded label for kidney drug despite failed trial

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Biohaven lands priority review on second-chance application for neurodegenerative drug

What will pharma's share buyback shopping spree mean for M&A?

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Hous­ton’s huge R&D hub takes cen­ter stage in feds’ cam­paign to clip Chi­na’s ties to re­searchers, IP theft

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Houston’s huge R&D hub takes center stage in feds’ campaign to clip China’s ties to researchers, IP theft